SequelSEC

Bone Biologics Corp BBLG

Orthopedic, Prosthetic & Surgical Appliances & Supplies · CIK 0001419554 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2021-06-30
Operating income
-$231.88K
Fiscal year ended 2021-06-30
Free cash flow
Unavailable
Fiscal year ended 2021-06-30

Bone Biologics Corp (BBLG) reported revenue of $0 and net income of -$491.90K for the fiscal year ended 2021-06-30. This page shows 8 annual periods of income statement, balance sheet and cash flow figures normalized from Bone Biologics Corp’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Orthopedic, Prosthetic & Surgical Appliances & Supplies.

Income

Bone Biologics Corp income by fiscal year, in US dollars, normalized from SEC filings.
Metric2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312016-12-31
Revenue$0$1.07B$0$0$0$1.07BUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$231.88K-$180.92K-$206.43K-$145.82K-$132.71K-$340.05KUnavailableUnavailable
Net income-$491.90K-$431.75K-$453.71K-$394.05K-$380.03K-$596.90KUnavailableUnavailable
Research & development$2.02K$45.50K$21.69K$142.88K$9.00K$167.10KUnavailableUnavailable
Weighted-average diluted sharesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Pretax income-$491.90K-$431.75K-$453.71K-$394.05K-$380.03K-$595.30KUnavailableUnavailable
Income tax expenseUnavailableUnavailable$0$0$0$1.60KUnavailableUnavailable
Diluted EPSUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$229.86K$135.42K$184.74K$2.95K$123.71K$172.95KUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Bone Biologics Corp balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312016-12-31
Cash & equivalents$4.44K$71.16KUnavailable$2.46KUnavailable$2.43K$24.14KUnavailable
Total assets$4.44K$71.16K$0UnavailableUnavailable$6.96K$30.83KUnavailable
Current assetsUnavailableUnavailableUnavailable$2.46K$1.43KUnavailable$30.83KUnavailable
Total liabilities$14.62M$14.20M$13.69M$13.24M$12.85M$12.47M$11.90MUnavailable
Current liabilitiesUnavailableUnavailable$13.69M$13.24M$12.85M$12.47M$578.45KUnavailable
Total equity incl. NCI-$14.62M-$14.12M-$13.69M-$13.24M-$12.84M-$12.46M-$11.87MUnavailable
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailable$465.40K$399.66K$248.60K$213.13K$42.88KUnavailable

Cash flow

Bone Biologics Corp cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312016-12-31
Operating cash flow-$635.98K-$127.98K-$125.69K-$72.23K-$79.13K-$149.88KUnavailableUnavailable
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Financing cash flow$569.25K$199.15K$123.23K$74.69K$76.70K$128.16KUnavailableUnavailable
Net change in cash-$66.73K$71.16K-$2.46K$2.46K-$2.43K-$21.71KUnavailableUnavailable
Stock-based compensationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Bone Biologics Corp derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312016-12-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratioUnavailableUnavailableUnavailable0.00x0.00xUnavailableUnavailableUnavailable
Revenue YoY growthUnavailable0.0%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BBLG in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-03-02View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-12View SEC filing

Companies in the same industry

Reconciliation checks needing review

2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2016-12-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2016-12-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.